Novartis announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion r...
Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. announced new real-world data evaluating treatment continuity, health...
Flow Neuroscience announced that FL-100 is now available by prescription across the United States, introducing the first FDA-approved at-home transc...
Ingelheim, Germany - Boehringer Ingelheim announced the launch of PED Essentials, a comprehensive e-learning hub designed to help patient organizations g...
AptarGroup, Inc. (NYSE:ATR), a global leader in drug delivery, dosing and protection technologies, and consumer product dispensing, announced that it has...
All 24 patients completed treatment with no dose-limiting toxicities, no Grade 3 or higher adverse events related to JNJ-1900 (NBTXR3 or to the injecti...
Bio Usawa and Axmed have entered into a strategic collaboration to expand patient access to advanced, affordable biologic medicines across African health...
Approximately 600 patients expected to be enrolled at clinical sites across the United States, Europe, China and South America Global Phase 3 program, R...
Insilico Medicine ("Insilico," HKEX: 3696), a clinical-stage biotechnology company powered by generative AI, announced that it has dosed the first patien...
Bone Biologics Corporation (Nasdaq: BBLG, BBLGW) (“Bone Biologics” or the “Company”), a developer of orthobiologic products for s...
Adds gildeuretinol (ALK-001), a differentiated Phase 3 oral investigational medicine designed to target the underlying biology of Stargardt’s disea...
NexLife, a LegitScript-certified, physician-led telehealth platform, announced that its compounded GLP-1 program now spans four protocols under a single ...
10x Genomics, Inc., the life science technology leader focused on accelerating science and advancing human health, announced that a jury in the U.S. Dist...
Roche announced new two-year data from the Phase IIIb/IV SALWEEN study of Vabysmo® (faricimab), presented at the 19th Asia-Pacific Vitreo-retina Soci...
© 2026 Biopharma Boardroom. All Rights Reserved.
